RIFAMPIN
ACTIVE TUBERCULOSIS·+3
VERSA PHARMACEU
Indication
Meningococcal carrier
A meningococcal carrier is an individual with asymptomatic colonization of the nasopharyngeal mucosa by the bacterium *Neisseria meningitidis* without clinical evidence of invasive disease. Read more about Meningococcal carrier
67 drugs 51 manufacturers
Drugs that treat it
Common Meningococcal carrier therapies.
RIFADIN (rifampin)
RIFAMYCINS·ACTIVE TUBERCULOSIS·+3
Sanofi-Aventis U.S.
MINOCIN (minocycline HCl)
CHOLERA·+34
ONSET THERAPEUT
MINOCYCLINE HCL
CHOLERA·+34
RANBAXY PHARMAC
MINOCYCLINE (minocycline HCl)
CHOLERA·+34
WATSON LABS
MINOCIN (minocycline HCl)
CHOLERA·+34
REMPEX PHARMACE
MINOCYCLINE HCL
CHOLERA·+34
CARACO PHARM
MINOCYCLINE HCL
CHOLERA·+34
ACTAVIS PHARMA,
RIFAMPIN
RIFAMYCINS·ACTIVE TUBERCULOSIS·+3
LUPIN PHARMACEU
Filter & compare in the drug finder →Opens the drug finder with Meningococcal carrier preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonA meningococcal carrier is an individual with asymptomatic colonization of the nasopharyngeal mucosa by the bacterium *Neisseria meningitidis* without clinical evidence of invasive disease.
This carrier state primarily affects the upper respiratory epithelium and peaks in prevalence among adolescents and young adults residing in dense social settings.
Pathophysiologically, the bacteria utilize surface structures, such as type IV pili and outer membrane adhesins, to adhere to nonciliated nasopharyngeal epithelial cells and establish a commensal reservoir.
While the vast majority of carriers remain completely asymptomatic, colonized hosts serve as the principal reservoir for person-to-person transmission via respiratory droplets and harbor a potential risk for mucosal breach leading to invasive meningococcemia or meningitis.
- gov.uk
A meningococcal carrier is an individual with asymptomatic colonization of the nasopharyngeal mucosa by the bacterium *Neisseria meningitidis* without clinical evidence of invasive disease This carrier state primarily affects the upper respiratory epithelium and peaks in prevalence among adolescents and young adults residing in dense social settings While the vast majority of carriers remain completely asymptomatic, colonized hosts serve as the principal reservoir for person-to-person transmissi...
- nih.gov
Pathophysiologically, the bacteria utilize surface structures, such as type IV pili and outer membrane adhesins, to adhere to nonciliated nasopharyngeal epithelial cells and establish a commensal reservoir
- nih.gov
Pathophysiologically, the bacteria utilize surface structures, such as type IV pili and outer membrane adhesins, to adhere to nonciliated nasopharyngeal epithelial cells and establish a commensal reservoir
- nih.gov
While the vast majority of carriers remain completely asymptomatic, colonized hosts serve as the principal reservoir for person-to-person transmission via respiratory droplets and harbor a potential risk for mucosal breach leading to invasive meningococcemia or meningitis
- pharmacytimes.com
While the vast majority of carriers remain completely asymptomatic, colonized hosts serve as the principal reservoir for person-to-person transmission via respiratory droplets and harbor a potential risk for mucosal breach leading to invasive meningococcemia or meningitis
Personalize your experience
Follow Meningococcal carrier and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.